AI-Driven Cognitive Digital Therapeutics for Dementia Management
ConditionCognitive Impairment
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50+
SponsorTaipei Medical University WanFang Hospital
About this trial
The study would investigate the effect of a cognitive digital therapeutics system. The intervention group would receive three digital therapeutics sessions per week for 8 weeks, while the control group would receive usual care. Evaluations would be done at baseline, week 8, and week 16.
Eligibility criteria
Qualifiers
Age at least 50 years old.
Clinical Dementia Rating from 0.5-1
Physician diagnosed mild neurocognitive disorder or dementia (according to ICD-11 diagnostic criteria)
Disqualifiers
Mini-mental state examination score below 18
If receiving an approved Alzheimer's disease treatment such as acetylcholinesterase inhibitor (AChEIs) or memantine or both for Alzheimer's disease, must be on a stable dose for at least 4 weeks prior to Baseline.
Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the participant's mild neurocognitive disorder or dementia.
History of transient ischemic attacks (TIA), stroke, or seizures within 12 months of Screening.
Trial design
Treatments tested in this trial
- Digital therapeutics session
Treatment groups
30 Participants
are divided into 2 treatment groupsLocations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Taipei Medical University Wan Fang HospitalRecruiting116, Taipei City, Taipei
Taiwan
TaiwanSponsors and collaborators
Source ClinicalTrials.gov